REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase III clinical trial for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I, RGX-181 for the treatment of late-infantile neuronal ceroid lipofuscinosis type 2, and RGX-381 for the treatment of the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.

Period	Debt/Equity
2016-12-31	0.07
2017-12-31	0.09
2018-12-31	0.07
2019-12-31	0.11
2020-12-31	0.87
2021-12-31	0.46
2022-12-31	0.61
2023-12-31	0.84
2024-12-31	0.79
2025-12-31	3.41

	A	B	C	D
1	Symbol	Price	Change	Volume
2	RGNX	$7.80	-1.27%	3.21M
3
4
5

REGENXBIO Inc. (RGNX) Debt to Equity Ratio

Debt to Equity Ratio Data

Get REGENXBIO Inc. Data in Excel

More RGNX Financial Data